U.S. President Donald Trump on Friday said he would probably meet Ukrainian President Volodymyr Zelenskiy next week to discuss Ukraine's war to repel Russian invaders. Trump says he may meet ...

SCOTTSDALE, AZ — A referendum petition related to Axon Enterprise Inc.'s sprawling Scottsdale headquarters has been certified, clearing a path for voters to weigh in on the proposed development.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

This page features the latest news about the Apellis Pharma share. Mizuho maintains Neutral rating on Apellis stock, price target $30 Tuesday, Mizuho (NYSE:MFG) Securities reiterated its Neutral ...

Analyst Judah Frommer of Morgan Stanley maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price target of $31.00. Judah Frommer’s rating is based on ...

WALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE ...

Apellis Pharmaceuticals, Inc. announced that the Therapeutic Goods Administration (TGA) in Australia has approved its treatment SYFOVRE® (pegcetacoplan) for adult patients suffering from ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Analysts at William Blair upped their FY2024 earnings estimates for Apellis Pharmaceuticals in a report issued on Tuesday, January 21st.